Latest Safety News

Page 17 of 252
Dimerix has secured Mexican composition of matter protection for its Phase 2-ready kidney drug DMX-652 until June 2041. The grant expands the asset’s patent estate ahead of planned clinical testing in acute kidney injury, although it brings no new clinical data or regulatory approval.
Victor Sage
Victor Sage
14 Sept 2026
Forrestania Resources has signed agreements giving it access to up to 2 million tonnes of third-party ore and a five-year framework for future mining services. Initial supply is expected from stockpiles at MEGA Resources’ Taipan open pit, although volumes, timing and financial returns remain uncommitted.
Maxwell Dee
Maxwell Dee
14 Sept 2026
Paradigm Biopharmaceuticals has drawn the remaining US$2 million available in Tranche 4 of its convertible note facility, adding approximately A$2.8 million to working capital. The funding comes as its fully enrolled Phase 3 knee osteoarthritis trial advances towards interim analysis and top-line results.
Victor Sage
Victor Sage
11 Sept 2026
Immutep has narrowed eftilagimod alfa’s potential registration pathway to PD-L1-negative head and neck cancer and neoadjuvant soft tissue sarcoma after identifying product differences between manufacturing scales used in earlier studies and TACTI-004. A new 200 L manufacturing run is planned, but replacement trials are not targeted to start until the second half of 2027 and remain subject to regulatory, funding and partnering decisions.
Ada Torres
Ada Torres
11 Sept 2026
WasteCo is asking eligible New Zealand shareholders for up to NZ$750,000 in fresh equity as it tackles NZ$40.1 million of debt, a FY2026 loss and an aggressive operational reset. The non-underwritten plan follows a separate placement and is priced at NZ$0.007 per share.
Maxwell Dee
Maxwell Dee
11 Sept 2026
Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.
Ada Torres
Ada Torres
10 Sept 2026
GrainCorp says its transformation program is on track to deliver $12 million in run-rate benefits by the end of FY26, above the top of its previous commitment. But the company has delayed a major systems rollout, expects $30-35 million of FY27 completion spend and deferred a second release.
Victor Sage
Victor Sage
10 Sept 2026
A multimillion-dollar, multiyear NIH grant will fund an expanded access program for Neurizon’s investigational NUZ-001, potentially giving up to 200 US patients access to the therapy for as long as 96 weeks. The program is designed to add long-term safety, survival and biomarker data alongside the pivotal HEALEY ALS trial.
Ada Torres
Ada Torres
9 Sept 2026
EV Resources has moved its Tecomatlán plant from integration into live proof-of-concept processing, with 200 metric tons of antimony ore delivered and crushing underway. The company is now targeting its first marketable antimony concentrate, although plant-scale performance remains unproven.
Maxwell Dee
Maxwell Dee
9 Sept 2026
The FDA has agreed that EBR Systems’ WiSE cardiac pacing system does not require a field corrective action or recall following a February cybersecurity incident. The device maker says it has found no evidence of any impact on the safety or performance of fielded systems, while remediation work continues.
Victor Sage
Victor Sage
9 Sept 2026
Polymetals Resources moved its Endeavor silver-zinc-lead mine from restart to commercial production in FY2026, generating A$100.0 million in revenue. The milestone came alongside a A$47.0 million loss, negative operating cash flow and an auditor warning over going-concern uncertainty.
Maxwell Dee
Maxwell Dee
8 Sept 2026
Emperor Energy has signed a term sheet to secure the Valaris 107 jack-up rig for its Judith-2 appraisal well, targeted for April 2027. The deal commits US$3.5 million before the full drilling contract is finalised, while environmental approval remains outstanding.
Victor Sage
Victor Sage
8 Sept 2026

Browse the archive

Full archive